This site is intended for healthcare professionals
  • Home
  • /
  • Clinical trials
  • /
  • Uncategorised Disease
  • /
  • EUCROSS: European Trial on Crizotinib in ROS1 Tran...
Clinical trial

EUCROSS: European Trial on Crizotinib in ROS1 Translocated Lung Cancer

Read time: 1 mins
Last updated:25th Jun 2014

EUCROSS is a phase II trial to evaluate the efficacy and safety of crizotinib in patients with adenocarcinoma of the lung harbouring ROS1 translocations. Patients will be treated with 250mg crizotinib bid untill progression or intolerable toxicity.

Category Value
Study start date 2014-06-25

View full details